134 related articles for article (PubMed ID: 30715324)
1. Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling.
Schalkwijk S; Ter Heine R; Colbers A; Capparelli E; Best BM; Cressey TR; Greupink R; Russel FGM; Moltó J; Mirochnick M; Karlsson MO; Burger DM
J Antimicrob Chemother; 2019 May; 74(5):1348-1356. PubMed ID: 30715324
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women.
Crauwels HM; Kakuda TN; Ryan B; Zorrilla C; Osiyemi OO; Yasin S; Brown K; Verboven P; Hillewaert V; Baugh B
HIV Med; 2016 Oct; 17(9):643-52. PubMed ID: 27187894
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Safety of Darunavir/Ritonavir in HIV-Infected Pregnant Women.
Khoo S; Peytavin G; Burger D; Hill A; Brown K; Moecklinghoff C; La Porte C; Hadacek MB
AIDS Rev; 2017; 19(1):16-23. PubMed ID: 28182610
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women.
Colbers A; Moltó J; Ivanovic J; Kabeya K; Hawkins D; Gingelmaier A; Taylor G; Weizsäcker K; Sadiq ST; Van der Ende M; Giaquinto C; Burger D;
J Antimicrob Chemother; 2015 Feb; 70(2):534-42. PubMed ID: 25326090
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.
Lê MP; Chaix ML; Chevret S; Bertrand J; Raffi F; Gallien S; El Abbassi EMB; Katlama C; Delobel P; Yazdanpanah Y; Saillard J; Molina JM; Peytavin G;
J Antimicrob Chemother; 2018 Aug; 73(8):2120-2128. PubMed ID: 29905808
[TBL] [Abstract][Full Text] [Related]
6. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily.
Zorrilla CD; Wright R; Osiyemi OO; Yasin S; Baugh B; Brown K; Coate B; Verboven P; Mrus J; Falcon R; Kakuda TN
HIV Med; 2014 Jan; 15(1):50-6. PubMed ID: 23731450
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
Arab-Alameddine M; Lubomirov R; Fayet-Mello A; Aouri M; Rotger M; Buclin T; Widmer N; Gatri M; Ledergerber B; Rentsch K; Cavassini M; Panchaud A; Guidi M; Telenti A; Décosterd LA; Csajka C;
J Antimicrob Chemother; 2014 Sep; 69(9):2489-98. PubMed ID: 24821595
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women.
Stek A; Best BM; Wang J; Capparelli EV; Burchett SK; Kreitchmann R; Rungruengthanakit K; Cressey TR; Mofenson LM; Smith E; Shapiro D; Mirochnick M
J Acquir Immune Defic Syndr; 2015 Sep; 70(1):33-41. PubMed ID: 25950206
[TBL] [Abstract][Full Text] [Related]
9. Darunavir Pharmacokinetics With an Increased Dose During Pregnancy.
Eke AC; Stek AM; Wang J; Kreitchmann R; Shapiro DE; Smith E; Chakhtoura N; Capparelli EV; Mirochnick M; Best BM;
J Acquir Immune Defic Syndr; 2020 Apr; 83(4):373-380. PubMed ID: 31923087
[TBL] [Abstract][Full Text] [Related]
10. Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach.
Dickinson L; Winston A; Boffito M; Khoo S; Back D; Siccardi M
J Antimicrob Chemother; 2016 Apr; 71(4):1041-5. PubMed ID: 26712906
[TBL] [Abstract][Full Text] [Related]
11. Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection.
Calza L; Colangeli V; Magistrelli E; Bussini L; Conti M; Ramazzotti E; Mancini R; Viale P
HIV Med; 2017 Aug; 18(7):474-481. PubMed ID: 28116848
[TBL] [Abstract][Full Text] [Related]
12. Reduced exposure to darunavir and cobicistat in HIV-1-infected pregnant women receiving a darunavir/cobicistat-based regimen.
Crauwels HM; Osiyemi O; Zorrilla C; Bicer C; Brown K
HIV Med; 2019 May; 20(5):337-343. PubMed ID: 30873741
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring of darunavir/ritonavir in pregnancy.
Murtagh R; Else LJ; Kuan KB; Khoo SH; Jackson V; Patel A; Lawler M; McDonald G; Le Blanc D; Avramovic G; Redmond N; Lambert JS
Antivir Ther; 2019; 24(3):229-233. PubMed ID: 30728322
[TBL] [Abstract][Full Text] [Related]
14. Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.
Colbers A; Greupink R; Litjens C; Burger D; Russel FG
Clin Pharmacokinet; 2016 Mar; 55(3):381-96. PubMed ID: 26369773
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals.
Jackson A; Else L; Higgs C; Karolia Z; Khoo S; Back D; Devitt E; Pozniak A; Boffito M
HIV Clin Trials; 2018 Feb; 19(1):31-37. PubMed ID: 29189101
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic Evaluation of Darunavir Administered Once or Twice Daily in Combination with Ritonavir or the Three-Direct-Acting Antiviral Regimen of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults Coinfected with Hepatitis C and Human Immunodeficiency Viruses.
King JR; Khatri A; Trinh R; Viani RM; Ding B; Zha J; Menon R
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27919899
[TBL] [Abstract][Full Text] [Related]
17. Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial.
Pressiat C; Hirt D; Treluyer JM; Zheng Y; Morlat P; Naqvi A; Tran L; Viard JP; Avettand-Fenoel V; Rouzioux C; Meyer L; Cheret A;
J Antimicrob Chemother; 2018 Apr; 73(4):1020-1024. PubMed ID: 29365125
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children.
Bastiaans DET; Geelen SPM; Visser EG; van der Flier M; Vermont CL; Colbers APH; Roukens M; Burger DM; van Rossum AMC;
Pediatr Infect Dis J; 2018 Oct; 37(10):1008-1010. PubMed ID: 29474261
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling.
Schalkwijk S; Buaben AO; Freriksen JJM; Colbers AP; Burger DM; Greupink R; Russel FGM
Clin Pharmacokinet; 2018 Jun; 57(6):705-716. PubMed ID: 28744795
[TBL] [Abstract][Full Text] [Related]
20. Exploration of Reduced Doses and Short-Cycle Therapy for Darunavir/Cobicistat in Patients with HIV Using Population Pharmacokinetic Modeling and Simulations.
Stillemans G; Belkhir L; Vandercam B; Vincent A; Haufroid V; Elens L
Clin Pharmacokinet; 2021 Feb; 60(2):177-189. PubMed ID: 32696441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
